Sarepta Therapeutics Announces Positive Results in Its Study Evaluating Gene Expression, Dystrophin Production, and Dystrophin Localization in Patients with Duchenne Muscular Dystrophy (DMD) Amenable
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sarepta (SRPT) SRP-4053 Data Provides 'Strong Validation' - SunTrust
September 6, 2017 11:54 AM EDTSunTrust Robinson Humphrey analyst Edward Nash reiterated a Buy rating and $56 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive muscle biopsy results from the Phase I/II 4053-101 study that evaluated golodirsen (SRP-4053) for the treatment of DMD patients... More
Sarepta (SRPT) Could See Exon 53 Approval in 2018, Peak Sales of ~$800M - William Blair
September 6, 2017 11:06 AM EDTWilliam Blair analyst Tim Lugo weighed in on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced positive interim 48-week data from its ongoing European Phase I/II study for DMD patients amenable to skipping exon 53 with golodirsen (SRP-4053).
Lugo notes all... More
UPDATE: Sarepta Therapeutics (SRPT) PT Raised to $55 at Piper Jaffray
September 6, 2017 10:57 AM EDT(Updated - September 6, 2017 11:00 AM EDT)
(updated to add analyst comment)
Piper Jaffray raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $55.00 (from $50.00) while maintaining a Overweight rating.
Analyst Edward Tenthoff notes the positive Exon 53 data. The analyst further comments... More
Sarepta Therapeutics (SRPT): Needham & Company Highlights 2 Significant Positive Implications from Dolodiresen Data
September 6, 2017 8:42 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $75 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company reported positive Phase I/II data for golodiresen, an exon 53 skipping therapy for Duchenne's muscular dystrophy (DMD).
Messer highlights s 2 significant positive... More
Sarepta (SRPT) SRP-4053 Data Strengthen Case for Exon Expansion Approach - Baird; Reit. OP, $101 PT
September 6, 2017 8:30 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $101 price target on Sarepta Therapeutics (NASDAQ: SRPT) following positive European Phase 1/2 study of SRP-4053.
Skorney said this strengthens the case for Sarepta's approach to exon expansion.
"With dystrophin expression exceeding that... More
